Anti-Human Rhinoviral Activity of Polybromocatechol Compounds Isolated from the Rhodophyta, Neorhodomela aculeata

Marine Drugs

Soon-Hye Park¹  Jae-Hyoung Song²  Taejung Kim¹  Woon-Seob Shin⁴  Gab Man Park⁴  Seokjoon Lee⁴  Young-Joo Kim¹  Pilju Choi¹  Heejin Kim¹  Hui-Seong Kim³  Dur-Han Kwon³  Hwa Jung Choi² 

[1] Marine Chemomics Lab., Natural Medicine Center, Korea Institute of Science and Technology, Gangneung 210-340, Korea;Zoonosis Research Center, Wonkwang University College of Medicine & Oriental Medicine, 344-2, Iksan, Chonbuk 570-749, Korea;Immune Modulator Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon 305-333, Korea;Department of Microbiology and Basic Science, Kwandong University College of Medicine, Gangneung 210-701, Korea;

关键词: Neorhodomelaaculeate;    red alga;    polybromocatechol compounds;    antiviral activity;    human rhinovirus;   

DOI  :  10.3390/md10102222

来源: mdpi

【 摘 要 】

An extract of the red alga, Neorhodomela aculeata, exhibited antiviral activity against human rhinoviruses. Bioassay-guided purification was performed to yield six compounds, which were subsequently identified as lanosol (1) and five polybromocatechols (2–6) by spectroscopic methods, including 1D and 2D NMR and mass spectrometric analyses. Structurally, all of these compounds, except compound 5, contain one or two 2,3-dibromo-4,5-dihydroxyphenyl moieties. In a biological activity assay, compound 1 was found to possess antiviral activity with a 50% inhibitory concentration (IC₅₀) of 2.50 μg/mL against HRV2. Compound 3 showed anti-HRV2 activity, with an IC₅₀ of 7.11 μg/mL, and anti-HRV3 activity, with an IC₅₀ of 4.69 μg/mL, without demonstrable cytotoxicity at a concentration of 20 μg/mL. Collectively, the results suggest that compounds 1 and 3 are candidates for novel therapeutics against two different groups of human rhinovirus.

【 授权许可】

CC BY   
© 2012 by the authors; licensee MDPI, Basel, Switzerland.